Medimmune Limited

University of Colorado

University of Rochester

Michael P McCarthy

JoAnn A Suzich

Robert L Garcea

Robert C Rose

JoAnne A Suzich

Charles K Stover

Antonio Digiandomenico

Hasan Jafri

Xiang-Qing Yu

Brian Bishop

A method for preventing or treating nosocomial diseases, e.g., diseases caused by, is provided. The method includes administering to a susceptible human subject a specified dose of a bispecific antibody that specifically bindsPsl and PcrV.

Method for preventing or treating nosocomial pneumonia

A method of disassembly/reassembly of papillomavinis VLPs is provided. The resultant VLPs have enhanced homogeneity, present conformational, neutralizing PV epitopes, and therefore are useful prophylactic and diagnostic agents. Further, these VLPs can be used to encapsulate desired moieties, e.g., therapeutic or diagnostic agents, or marker' DNAs, and the resultant VLPs used as in vivo delivery vehicles or as pseudovirions for evaluating vaccine efficacy.

In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents

A method of disassembly/reassembly of papillomavirus VLPs is provided. The resultant VLPs have enhanced homogeneity, present conformational, neutralizing PV epitopes, and therefore are useful prophylactic and diagnostic agents. Further, these VLPs can be used to encapsulate desired moieties, e.g., therapeutic or diagnostic agents, or 'marker' DNAs, and the resultant VLPs used as in vivo delivery vehicles or as pseudovirions for evaluating vaccine efficacy.

IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPS), HOMOGENEOUS VLP AND CAPSOMERE COMPOSITIONS PRODUCED BY SAID METHODS; USE THEREOF AS VEHICLE FOR IMPROVED PURIFICATION, AND DELIVERY OF ACTIVE AGENTS

A method of disassembly/reassembly of papillomavirus VLPs is provided. The resultant VLPs have enhanced homogeneity, present conformational, neutralizing PV epitopes, and therefore are useful prophylactic and diagnostic agents. Further, these VLPs can be used to encapsulate desired moieties, e.g., therapeutic or diagnostic agents, or &ldquo;marker&rdquo; DNAs, and the resultant VLPs used as in vivo delivery vehicles or as pseudovirions for evaluating vaccine efficacy.

Vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPS)

In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)

The present invention relates to stable HPV capsomeres which express at least one virus-neutralizing conformational epitope of a native HPV L1 protein which are substantially incapable of assembly into virus-like particles. These capsomeres, because of their smaller size, and immunogenic properties are well suited for use in HPV vaccines and as diagnostic agents. Moreover, because of their smaller size (relative to VLPs), these stable capsomeres may be easily purified and should result in HPV vaccines of enhanced homogeneity.

Growing community of inventors

Poolesville, MD, United States of America

Michael P McCarthy